低分子肝素联合厄贝沙坦治疗肺心病心力衰竭的疗效观察

摘要

Objective To study and analyze the elinica effects of pulmonary heart failure patients treated with Low Molecular Weight Heparin combined with Irbesartan. Methods 90 cases of pulmonary heart failure patients were selected and divided into group A and B. Each group contained 45 cases. The two groups were given Low Molecular Weight Heparin and Low Molecular Weight Heparin with Irbesartan treatment respectively. Results The clinical curative effects of group B (93.3%) were obviously better than that of the group A (77.8%); the improvement of heart and lung function of group B was obviously higher than the group A; the disease occurs repeatedly over time of group B (9 cases) was significantly less than the number of patients in group A (2 cases); and there were no complications or adverse reactions in these two groups' treatment process. Conclusion The clinical effects of pulmonary heart failure patients treated with Low Molecular Weight Heparin with irbesartan is very obvious.%目的 对采用低分子肝素与厄贝沙坦联合对肺心病心力衰竭的患者进行治疗的临床效果进行研究分析.方法 抽取90例肺心病心力衰竭患者,将其分为A、B两组,平均每组45例.分别采用低分子肝素和低分子肝素与厄贝沙妊联合进行治疗.结果 B组患者治疗总有效率(93.3％)明显高于A组患者(77.8％)；该组患者治疗后一段时间病情发生反复的人数(9例)明显少于A组患者(2例)；两组患者治疗过程中没有出现并发症和不良反应现象.结论 采用低分子肝素与厄贝沙坦联合对肺心病心力衰竭的患者进行治疗的临床效果非常明显.